Post by ICON plc

ICON Laboratories now offers comprehensive blood-based biomarker testing for Alzheimer’s disease and neurodegenerative disorders—supporting earlier detection, improved patient access, and smarter clinical development strategies. Aligned with the latest AT(N) framework, our integrated portfolio includes plasma, CSF, and genetic biomarkers to enable end-to-end CNS clinical development. Discover how we’re helping sponsors accelerate innovation in neurology. https://ow.ly/HYry50ZbMpu #Alzheimers #CNS #ClinicalTrials #Biomarkers #PrecisionMedicine